Skip to Main Content

Author Details

Shalin Kothari
Yale University
2013
22
6
Wade Schulz (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36269847Postibrutinib relapse outcomes for patients with marginal zone lymphoma.Blood Adv2023
36993619Targeted engagement of β-catenin-Ikaros complexes in refractory B-cell malignancies.bioRxiv2023
37312418Microfluidic Immuno-Serolomic Assay Reveals Systems Level Association with COVID-19 Pathology and Vaccine Protection.Small Methods2023
37171397High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study.Blood Adv2023
36655436Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis.Haematologica2023
36651837Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters.Oncologist2023
36534735Genetic Modeling of B-cell State Transitions for Rational Design of Lymphoma Therapies.Blood Cancer Discov2023
35240689Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis.Blood Adv2022
35842643Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.J Hematol Oncol2022
36093346Microfluidic immuno-serology assay revealed a limited diversity of protection against COVID-19 in patients with altered immunity.bioRxiv2022
35157770A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome.Blood Adv2022
34589432Comprehensive Clinicopathologic and Molecular Analysis of Mast Cell Leukemia With Associated Hematologic Neoplasm: A Report and In-Depth Study of 5 Cases.Front Oncol2021
32518952Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia.Blood2020
31945157Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics.Blood Adv2020
33073261Pevonedistat, a NEDD8-Activating Enzyme Inhibitor, Induces Apoptosis and Augments Efficacy of Chemotherapy and Small Molecule Inhibitors in Pre-clinical Models of Diffuse Large B-cell Lymphoma.EJHaem2020
32835553Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.Leuk Lymphoma2020
30615550Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.J Clin Oncol2019
30671912Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?Curr Hematol Malig Rep2019
28682685Striking a Happy Medium.J Clin Oncol2017
27301488Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: a case report.J Med Case Rep2016
26510751Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction.J Thromb Thrombolysis2016
23476896Multiple isolated extramedullary relapse of acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplant: a case report and review of literature.Springerplus2013
  • 1 - 22 of 22

Recommended Authors

Mayo Clinic Arizona
Career Start Year 2015
Number of shared co-authors 0
Oregon Health & Science University
Career Start Year 2015
Number of shared co-authors 0
Weill Cornell Medicine and New York Presbyterian Hospital
Career Start Year 2013
Number of shared co-authors 1
Huntsman Cancer Institute at the University of Utah.
Career Start Year 2012
Number of shared co-authors 0
School of Clinical Sciences at Monash Health, Monash University
Career Start Year 2011
Number of shared co-authors 0
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2011
Number of shared co-authors 1
Mayo Clinic
Career Start Year 2010
Number of shared co-authors 0
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 2009
Number of shared co-authors 0
Universite de Paris, Inserm CIC 1427
Career Start Year 2009
Number of shared co-authors 0
The University of Texas Southwestern Medical Center
Career Start Year 2009
Number of shared co-authors 0
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 0
The Ohio State University
Career Start Year 2008
Number of shared co-authors 2
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 2006
Number of shared co-authors 1
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 0
City of Hope National Medical Center
Career Start Year 2005
Number of shared co-authors 2
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 0
Oregon Health and Science University
Career Start Year 2004
Number of shared co-authors 0
Division of Clinical Trials and Biostatistics, Mayo Clinic
Career Start Year 2001
Number of shared co-authors 0
Merck & Co.
Career Start Year 1998
Number of shared co-authors 2
University of Texas M.D. Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 1
School of Clinical Medicine, University of Hong Kong
Career Start Year 1997
Number of shared co-authors 2
University Hospital of Schleswig-Holstein
Career Start Year 1997
Number of shared co-authors 0
Center for Lymphoid Malignancies, Columbia University Medical Center
Career Start Year 1997
Number of shared co-authors 0
AbbVie Inc.
Career Start Year 1996
Number of shared co-authors 0
Duke University Medical Center
Career Start Year 1995
Number of shared co-authors 3
MD Anderson Cancer Center
Career Start Year 1992
Number of shared co-authors 0
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1990
Number of shared co-authors 0
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 2
The University of Texas MD Anderson Cancer Center
Career Start Year 1982
Number of shared co-authors 2

Collaborators

Yale School of Medicine
Co-authored papers 3
Smilow Cancer Center, Yale University School of Medicine
Co-authored papers 3
The Ohio State University Wexner Medical Center
Co-authored papers 2
City of Hope National Medical Center
Co-authored papers 2
Yale Cancer Center and Yale School of Medicine
Co-authored papers 2
Institute of Medicine, University of Tsukuba
Co-authored papers 2
Co-authored papers 2
Yale University
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Yale School of Medicine, Yale School of Public Health
Co-authored papers 2
Yale University
Co-authored papers 2
Yale School of Medicine
Co-authored papers 2
Yale Cancer Center and Smilow Cancer Hospital, Yale University School of Medicine
Co-authored papers 2
Yale University School of Medicine
Co-authored papers 2
University of California san francisco
Co-authored papers 1
Yale University
Co-authored papers 1
Yale University
Co-authored papers 1
Co-authored papers 1
University of Michigan ann arbor
Co-authored papers 1
Rutgers Robert Wood Johnson Medical School
Co-authored papers 1
Yale School of Medicine
Co-authored papers 1
Yale University
Co-authored papers 1
Yale University
Co-authored papers 1
Yale University
Co-authored papers 1
University of California san francisco
Co-authored papers 1
Institute of Pathogens and Vectors, Dali University
Co-authored papers 1
Yale University
Co-authored papers 1
University of California San Francisco
Co-authored papers 1
Co-authored papers 1